Company intelligence / Profile preview

Alysophil

Strasbourg, Grand Est, France

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Alysophil demonstrated fully autonomous chemical synthesis of APIs in continuous flow in a GMP-compliant system using AI (Deep Reinforcement Learning), with successful molecule synthesis for two API chemical entities under the PIPAc project. Results show lower energy/resource use, rapid cycle development, and reduced waste. Commercial pilot micro-plant expected to be operational by 2025.

Therapeutic areas: Other
Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

De Dietrich Process Systems (strategic investment and manufacturing partnership)NovAliX (API chemistry, drug discovery CRO collaboration)Bruker (Process Analytics and NMR solutions)Bpifrance (Project funding partner)

Beyond the preview

Go deeper on Alysophil.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alysophil.

Explore the full profile